<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01538771</url>
  </required_header>
  <id_info>
    <org_study_id>DAMI</org_study_id>
    <nct_id>NCT01538771</nct_id>
  </id_info>
  <brief_title>Intracoronary Darbepoetin-alpha to Reduce The Infarct Size and Post-Infarct Remodeling</brief_title>
  <official_title>The Efficacy of IntraCoronary Erythropoietin Delivery BEfore Reperfusion: Gauging Infarct Size in Patients With Acute ST-segment Elevation Myocardial Infarction (ICEBERG).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Bundang Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, randomized and open label trial&#xD;
&#xD;
      Hypothesis&#xD;
&#xD;
        -  Infusion of intracoronary darbepoetin-alpha at the time of reperfusion may reduce&#xD;
           infarct size and post-infarct pathologic left ventricular remodeling in patients with&#xD;
           ST-segment elevation myocardial infarction.&#xD;
&#xD;
      Methods&#xD;
&#xD;
        -  Randomization into control group or treatment group&#xD;
&#xD;
        -  Treatment group : Darbepoetin-alpha 300ug intracoronary bolus infusion via over-the-wire&#xD;
           balloon system simultaneously with first balloon inflation and conventional treatment&#xD;
&#xD;
        -  Control group : conventional treatment&#xD;
&#xD;
      Endpoints&#xD;
&#xD;
        -  peak CK-MB &amp; troponin levels : baseline,6h,12hr,18hr, 24hr, 36hr and 48hr&#xD;
&#xD;
        -  MRI at baseline : infarct size, area at risk and salvaged myocardium&#xD;
&#xD;
        -  MRI at 4 months : prevalence of pathologic left ventricle remodeling (definition:&#xD;
           increase of end-diastolic volume index &gt; 20% compared to baseline)&#xD;
&#xD;
        -  safety endpoint : cardiac death, nonfatal myocardial infarction, stent thrombosis,&#xD;
           ischemic stroke, hospital readmission with heart failure or ischemic symptom, bleeding&#xD;
           and urgent target lesion revascularization&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      [Eligibility Criteria]&#xD;
&#xD;
      1. Patients, regardless of gender, at the age from 18 to 80 years were eligible if they had&#xD;
      within 12 hours of onset of ST-segment myocardial infarction that was decided to treat with&#xD;
      primary percutaneous coronary intervention.&#xD;
&#xD;
      [Exclusion criteria]&#xD;
&#xD;
        1. Uncontrolled congestive heart failure (Killip classes II and III, or cardiogenic shock)&#xD;
&#xD;
        2. History of malignancy&#xD;
&#xD;
        3. Serious hematological disease&#xD;
&#xD;
        4. Current infectious disease requiring antibiotic therapy&#xD;
&#xD;
        5. Baseline creatinine level &gt; 2.0 mg/dL or dependence on dialysis&#xD;
&#xD;
        6. Known hypersensitivity to or contraindication for heparin, aspirin, clopidogrel,&#xD;
           sirolimus, everolimus, contrast medium and darbepoetin-α&#xD;
&#xD;
      [Primary endpoint] Myocardial infarct size, estimated by measurement of peak levels of&#xD;
      cardiac biomarker (CK-MB and troponin-I of the patients was followed for 48 hours at every 6&#xD;
      hours)&#xD;
&#xD;
      [Secondary end points]&#xD;
&#xD;
        1. The infarct size, measured as the area of delayed enhancement seen with cardiac magnetic&#xD;
           resonance (CMR) imaging on average four days after ST-segment elevation myocardial&#xD;
           infarction (baseline)&#xD;
&#xD;
        2. The proportion of area at risk (AAR) and salvaged myocardium, calculated by formula;&#xD;
           [AAR - Infarct size] / AAR X 100 (%)&#xD;
&#xD;
        3. The change of left ventricular ejection fraction (LVEF), LV end-diastolic volume&#xD;
           (LVEDV), and LV end-systolic volume (LVESV) assessed by CMR between four days and four&#xD;
           months&#xD;
&#xD;
        4. LV remodeling index [(LVEDV at four months - baseline LVEDV) / baseline LVEDV X 100%]&#xD;
           and the incidence of pathologic LV remodeling (LV remodeling index &gt; 20%);&#xD;
&#xD;
      [Safety endpoints] The incidence of composites of the cardiovascular endpoints (cardiac&#xD;
      death, nonfatal myocardial infarction, stent thrombosis, ischemic stroke, hospital&#xD;
      readmission with heart failure or ischemic symptoms, bleeding and urgent target lesion&#xD;
      revascularization) assessed at four months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2009</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak CK-MB/ Troponin-I levels</measure>
    <time_frame>baseline, 6, 12,18,24,36,48hrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infarct size, area at risk and proportion of salvaged myocardium</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 4 days</time_frame>
    <description>Assessed by cardiac MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic left ventricle remodeling assessed by cardiac MRI</measure>
    <time_frame>4 months</time_frame>
    <description>Definition : Increase of end-diastolic volume of left ventricle &gt;20%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of left ventricular ejection fraction, LV end-diastolic volume , and LV end-systolic volume assessed by cardiac MRI</measure>
    <time_frame>Between four days and 4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composites of cardiovascular endpoints</measure>
    <time_frame>4 Months</time_frame>
    <description>ccardiac death, nonfatal myocardial infarction, stent thrombosis, ischemic stroke, hospital readmission with heart failure or ischemic symptoms, bleeding and target lesion revascularization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Received same volume of saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Darbepoetin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Darbepoetin alfa 300ug intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning &amp; conventional treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darbepoetin alfa</intervention_name>
    <description>Darbepoetin alfa 300ug intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning and conventional treatment</description>
    <arm_group_label>Darbepoetin group</arm_group_label>
    <other_name>Nesp PFS Prefilled Syringe (Jeilkirin Pharm. Korea)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control Saline</intervention_name>
    <description>Same volume of saline intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning and conventional treatment</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>0.9% normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with ST-elevation myocardial infarction (MI) within 12 hours of onset&#xD;
&#xD;
          -  Suitable coronary anatomy for PCI&#xD;
&#xD;
          -  Age &lt; 80 yrs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled congestive heart failure (Killip classes II and III, or cardiogenic&#xD;
             shock)&#xD;
&#xD;
          -  History of malignancy&#xD;
&#xD;
          -  Serious hematological disease&#xD;
&#xD;
          -  Current infectious disease requiring antibiotic therapy&#xD;
&#xD;
          -  Baseline creatinine level &gt; 2.0 mg/dL or dependence on dialysis&#xD;
&#xD;
          -  Known hypersensitivity to or contraindication for heparin, aspirin, clopidogrel,&#xD;
             sirolimus, everolimus, contrast medium and darbepoetin-α&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong-Ju Choi, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <zip>463707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>February 15, 2012</study_first_submitted>
  <study_first_submitted_qc>February 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2012</study_first_posted>
  <last_update_submitted>June 18, 2015</last_update_submitted>
  <last_update_submitted_qc>June 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Bundang Hospital</investigator_affiliation>
    <investigator_full_name>Dong-Ju Choi</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Myocardial infarction</keyword>
  <keyword>Erythropoietin</keyword>
  <keyword>Myocardial reperfusion injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Darbepoetin alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

